Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles
暂无分享,去创建一个
Z. Nemeth | L. Antonioli | Patricia A Barratt-Stopper | D. A. Bogdanovski | Samantha R. Paglinco | R. Rolandelli
[1] B. Molnár,et al. Changes of the cytokine profile in inflammatory bowel diseases. , 2012, World journal of gastroenterology.
[2] D. Wolf,et al. Community Perspectives: Combining Serology, Genetics, and Inflammation Markers for the Diagnosis of IBD and Differentiation Between CD and UC. , 2012, Gastroenterology & hepatology.
[3] H. Hammad,et al. Cellular networks controlling Th2 polarization in allergy and immunity , 2012, F1000 biology reports.
[4] R. Giannella,et al. Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease , 2012, Expert review of clinical immunology.
[5] E. Szigethy,et al. Inflammatory bowel disease. , 2011, Pediatric clinics of North America.
[6] T. Macdonald,et al. IL‐23/IL‐17 axis in IBD , 2010, Inflammatory bowel diseases.
[7] C. Fiocchi,et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis , 2010, Proceedings of the National Academy of Sciences.
[8] R. Blumberg. Inflammation in the Intestinal Tract: Pathogenesis and Treatment , 2009, Digestive Diseases.
[9] D. Bernardo,et al. High Levels of Proinflammatory Cytokines, but Not Markers of Tissue Injury, in Unaffected Intestinal Areas from Patients with IBD , 2009, Mediators of inflammation.
[10] T. Giese,et al. Transcript levels of different cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitis , 2009, BMC gastroenterology.
[11] S. Targan,et al. Recent advances in IBD pathogenesis: Genetics and immunobiology , 2008, Current gastroenterology reports.
[12] K. Maloy. The Interleukin‐23 / Interleukin‐17 axis in intestinal inflammation , 2008, Journal of internal medicine.
[13] B. Müller-Myhsok,et al. Role of the novel Th17 cytokine IL‐17F in inflammatory bowel disease (IBD): Upregulated colonic IL‐17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD , 2008, Inflammatory bowel diseases.
[14] A. Rizzo,et al. Regulation of gut inflammation and th17 cell response by interleukin-21. , 2008, Gastroenterology.
[15] J. Yamamoto-Furusho,et al. Novel genetic markers in inflammatory bowel disease. , 2007, World journal of gastroenterology.
[16] T. Macdonald,et al. New players in the cytokine orchestra of inflammatory bowel disease , 2007, Inflammatory bowel diseases.
[17] J. Kolls,et al. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease? , 2007, International immunopharmacology.
[18] J. A. Garrote,et al. The pattern of cytokine expression determines the degree of mucosal damage , 2007, Gut.
[19] T. Hansson,et al. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis , 2007, Scandinavian journal of clinical and laboratory investigation.
[20] R. Burakoff,et al. Use of antibiotics in the treatment of inflammatory bowel disease , 2006, Inflammatory bowel diseases.
[21] M. Vander Vliet,et al. A phase 1/2A Trial of STA 5326, an oral interleukin‐12/23 inhibitor, in patients with active moderate to severe Crohn's disease , 2006, Inflammatory bowel diseases.
[22] R. Sartor. Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis , 2006, Nature Clinical Practice Gastroenterology &Hepatology.
[23] J. Satsangi,et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.
[24] Thomas Lengauer,et al. Dissection of the Inflammatory Bowel Disease Transcriptome Using Genome-Wide cDNA Microarrays , 2005, PLoS medicine.
[25] S. Targan,et al. Bacterial flagellin is a dominant antigen in Crohn disease. , 2004, The Journal of clinical investigation.
[26] T. Giese,et al. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn’s disease , 2004, International Journal of Colorectal Disease.
[27] G. Bouma,et al. The immunological and genetic basis of inflammatory bowel disease , 2003, Nature Reviews Immunology.
[28] A. Andoh,et al. Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.
[29] T. Giese,et al. Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease , 2002, Virchows Archiv.
[30] R. Sartor. Induction of mucosal immune responses by bacteria and bacterial components. , 2001, Current opinion in gastroenterology.
[31] A. Kornbluth,et al. Immunomodulator therapy in inflammatory bowel disease , 2001, Current treatment options in gastroenterology.
[32] B. Vainer,et al. Established and emerging biological activity markers of inflammatory bowel disease. , 2000, The American journal of gastroenterology.
[33] S. Hanauer,et al. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. , 1999, Inflammatory bowel diseases.
[34] P. Reitsma,et al. Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease , 1998, Gut.
[35] J. Reimund,et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. , 1996, Gut.
[36] A. Kruse,et al. Cytokine expression in intestinal mucosal biopsies. In situ hybridisation of the mRNA for interleukin-1 beta, interleukin-6 and tumour necrosis factor-alpha in inflammatory bowel disease. , 1994, European cytokine network.
[37] R. Sartor,et al. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. , 1994, Gastroenterology.
[38] M. Kagnoff. Immunology of the intestinal tract. , 1993, Gastroenterology.
[39] S. Haskill,et al. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. , 1992, Gastroenterology.